Compare RBBN & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBBN | DNA |
|---|---|---|
| Founded | 1997 | 2008 |
| Country | United States | United States |
| Employees | N/A | 485 |
| Industry | EDP Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 493.4M | 455.8M |
| IPO Year | 2017 | N/A |
| Metric | RBBN | DNA |
|---|---|---|
| Price | $2.76 | $8.65 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 2 |
| Target Price | $4.67 | ★ $8.50 |
| AVG Volume (30 Days) | 813.5K | ★ 1.2M |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 170.97 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.97 | N/A |
| Revenue Next Year | $6.69 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.83 | $5.37 |
| 52 Week High | $4.29 | $17.58 |
| Indicator | RBBN | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 56.13 | 55.31 |
| Support Level | $2.69 | $7.69 |
| Resistance Level | $2.86 | $8.93 |
| Average True Range (ATR) | 0.14 | 0.68 |
| MACD | -0.00 | -0.08 |
| Stochastic Oscillator | 70.33 | 44.63 |
Ribbon Communications Inc provides communications technology to service providers and enterprises, offering software and high-performance hardware products, network solutions, and services for secure data and voice communications, as well as high-bandwidth networking for residential and enterprise customers across industries such as finance, education, government, utilities, and transportation. It operates through two segments: Cloud and Edge, which generate maximum revenue and deliver software-centric, cloud-native solutions for VoIP, VoLTE, VoNR, and unified communications, and IP Optical Networks, which support growing telecommunications traffic from 5G, distributed cloud computing, and other applications. The Company generates the majority of its revenue from the United States.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.